A New Hope for Depression: Compass Pathways’ Psilocybin Study Shows Promising Results

Millions Struggle With Depression

Millions of people struggle with depression, and for some, traditional medications don’t help. This is called treatment-resistant depression (TRD), and it affects about one in three people living with major depression. For those patients, each day can feel like an uphill battle with little relief in sight.

New Hope With Compass Pathways

Now, there may be new hope. Compass Pathways, a mental health research company, recently announced encouraging results from a large study testing COMP360, a synthetic form of psilocybin—the active ingredient found in certain mushrooms.

Phase 3 Trial Results

In the Phase 3 trial, over 250 participants with TRD received either a single dose of COMP360 or a placebo. Six weeks later, the people who took COMP360 had a significant improvement in their depression symptoms compared to those who did not.

Importantly, the trial’s safety board found no unexpected safety issues and no meaningful increase in suicidal thoughts compared to the placebo group.

A Psychedelic First

This is the first time a psychedelic-based treatment has reached this stage of testing in a Phase 3 trial, which is one of the final steps before possible FDA approval. If successful, COMP360 could become the first new type of treatment for TRD in decades.

Faster Relief Than Antidepressants

Unlike traditional antidepressants, which can take weeks or months to work and often require daily dosing, COMP360 showed benefits after just one session. For patients who have tried multiple medications without success, this could be life-changing.

Ongoing Research

Compass Pathways is continuing its research with another large Phase 3 study, COMP006, which will test different doses of COMP360. Results from that study are expected in 2026. The company will also discuss the findings with the FDA to determine the next steps toward approval.

The Burden of TRD

Depression is one of the leading causes of disability worldwide, and TRD carries an especially heavy burden, increasing risks of other illnesses and even suicide. The positive results from COMP360 bring much-needed hope to patients, families, and clinicians searching for better options.

A Milestone in Mental Health Treatment

While more research is needed, this study marks an important milestone in reimagining how we treat mental health. For many, it represents not just science in action—but hope for a brighter future.

Looking Ahead

Psilocybin therapy isn’t ready for doctor’s offices yet, but it’s on the horizon. If approved, it could provide relief for millions who have felt left behind by current depression treatments.

Melissa Huettner

Melissa is the Global Digital Strategy Lead for Interim Visits Magazine. She is an experienced CRA and Clinical Research Coordinator with experience in several therapeutic areas including oncology and ophthalmology.

Melissa is an experienced Clinical Research Associate (CRA) with experience in numerous therapeutic areas including ophthalmology, endocrinology and oncology. Melissa is also the Associate Editor of Interim Visits Magazine.

Outside of clinical research, Melissa is a beekeeper. She is the owner and manager her family’s apiary. Rabbit Hole Farms, in Eastern Tennessee. She eventually hopes to collaborate on clinical trials related to medicinal honey, bee venom, and/or bee allergies.